NARSAD
Donate
HomeAbout UsHow to HelpNews & EventsDisorders & ConditionsResearch Center

» Apply for a Grant
- FAQs
- Young Investigator
- Independent
    Investigator

- Distinguished
    Investigator

- Staglin Award

» Grantee List
- Young Investigators
- Independent
    Investigators

- Distinguished
    Investigators

- Staglin Awards


» Prizes
- Lieber Prize
- Falcone Prize
- Ruane Prize
- Goldman-Rakic Prize
- Freedman Award
- Klerman Award

» For Grantees
- Young Investigator
    Fact Sheet

- Independent
    Investigator
    Fact Sheet

- Distinguished
    Investigator
    Fact Sheet

- Staglin Award
    Fact Sheet


Stay Informed

 
Project Summary

EmailPrint

Brian A. Fallon, M.D., M.P.H., (Independent Investigator 2006) of Columbia University and the New York State Psychiatric Institute, aims to study if the antibiotic ceftriaxone may reduce psychosis in hospitalized schizophrenia patients. Research has shown ceftriaxone may have a unique neuroprotective effect by decreasing extracellular glutamate in the nervous system and by increasing glutamate transporter proteins. Glutamate is a major excitatory neurotransmitter which when dysregulated can cause problems with memory, attention, movement, sensation and perception. Although overactivity of the dopamine neurotransmitter system is believed to play a role in psychosis, other neurotransmitters, such as glutamate, may also be involved because not all patients respond to antipsychotic drugs that lower dopamine activity. Also, drugs that block the glutamate receptor NMDA cause symptoms of psychosis in healthy people, presumably by increased synaptic glutamate producing excitatory neurotoxicity. Agents that reduce excess glutamate activity are neuroprotective. Dr. Fallon has shown that ceftriaxone can improve cognition in patients with persistent cognitive deficits after Lyme disease. Whether the effect was due to its antimicrobial or glutamate effect is uncertain. The proposed study will investigate if the antibiotic can decrease psychotic symptoms in patients with refractory psychotic disorders. In this study, 28 patients undergoing standardized antipsychotic therapy will be randomly assigned to a 40 day treatment of either IV placebo or IV ceftriaxone. The first 20 patients will also have brain imaging using magnetic resonance spectroscopy before and after treatment to evaluate prefrontal cortical glutamatergic activity. Reduction in hallucinations and/or delusions and improved mood and cognition will be monitored. Findings may provide a new treatment for patients with refractory psychosis and a new way to study human glutamate activity.

Program Area: SCHIZOPHRENIA/PSYCHOTIC DISORDERS\Schizophrenia

Search Again

EmailPrint

 

 
Announcements
2008/2009 NARSAD Grant Deadlines:

2008 Young Investigator Earliest Start Date: July 1, 2008

2009 Young Investigator Award Application Deadline: July 25, 2008

2008 Independent Investigator Award Earliest Start Date: September 15, 2008

2008 Staglin Awards Earliest Start Date: September 15, 2008

2009 Independent Investigator Award Application Deadline: March 5, 2009

2009 Distinguished Investigator Earliest Start Date: May 1, 2009

2009 Young Investigator Earliest Start Date: July 1, 2009
NARSAD Award Winners
Latest News from NARSAD

 

 

 
NARSAD 60 Cutter Mill Road, Suite 404, Great Neck, New York 11021 USA     phone (800) 829-8289     fax (516) 487-6930     email info@narsad.org
©NARSAD 2008 | privacy policy | legal notices | disclaimers | sitemap | site help | contact us